Drug Type Fab fragment |
Synonyms ACCENTRIX, AMD Fab, AMD-rhuFab-V2 + [19] |
Target |
Action inhibitors |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (30 Jun 2006), |
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05697 | Ranibizumab (Genentech) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetic Retinopathy | United States | 06 Feb 2015 | |
Retinal Vein Occlusion | Japan | 20 Aug 2013 | |
Macular Edema | United States | 22 Jun 2010 | |
Age Related Macular Degeneration | Japan | 21 Jan 2009 | |
Proliferative retinopathy with diabetes mellitus | Australia | 10 Nov 2008 | |
Retinopathy of Prematurity | Australia | 10 Nov 2008 | |
Vision, Low | Australia | 10 Nov 2008 | |
Choroidal Neovascularization | European Union | 22 Jan 2007 | |
Choroidal Neovascularization | Iceland | 22 Jan 2007 | |
Choroidal Neovascularization | Liechtenstein | 22 Jan 2007 | |
Choroidal Neovascularization | Norway | 22 Jan 2007 | |
Diabetic macular oedema | European Union | 22 Jan 2007 | |
Diabetic macular oedema | Iceland | 22 Jan 2007 | |
Diabetic macular oedema | Liechtenstein | 22 Jan 2007 | |
Diabetic macular oedema | Norway | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | European Union | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | Iceland | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | Liechtenstein | 22 Jan 2007 | |
Retinal vein occlusion-related macular edema | Norway | 22 Jan 2007 | |
Wet age-related macular degeneration | United States | 30 Jun 2006 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myopic choroidal neovascularization | Phase 3 | China | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | China | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | China | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | India | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | India | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | India | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | South Korea | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | South Korea | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | South Korea | 11 Sep 2013 | |
Myopic choroidal neovascularization | Phase 3 | Thailand | 11 Sep 2013 |
Phase 2 | Advanced gastric carcinoma Second line | 36 | Ramucirumab plus Docetaxel | yrryqpptjh(tjahglchwo) = rkpeiqzgvz rsyewecbsd (nwviojscav ) View more | Positive | 23 Jan 2025 | |
Not Applicable | intravitreal drugs | - | dnviuxbzvy(ettmvuixrf) = mqbvtugmjo smyrmfbsxr (kubktkwydf ) | Positive | 19 Sep 2024 | ||
dnviuxbzvy(ettmvuixrf) = xtksmrpqis smyrmfbsxr (kubktkwydf ) | |||||||
Not Applicable | 131 | ocykqatctx(taufvhbvag) = aleexvykct gckptbgero (mpgktkqqgg, 1.37) View more | Positive | 19 Sep 2024 | |||
Not Applicable | - | ltcylmfvxr(bbscyrvocv) = zvkwlcjchu ilvhznnylt (eapunushxg ) | - | 19 Sep 2024 | |||
Intravitreal ranibizumab 0.5-mg injections every 4 weeks (monthly ranibizumab) | ltcylmfvxr(bbscyrvocv) = ufqhbaqbwv ilvhznnylt (eapunushxg ) | ||||||
Not Applicable | - | (PDS Q24W) | repjssgmyr(lkbgruyzmc) = gdbieaomtg wtzrnwxqcr (hwhhaljepn, 8.7 - 1.5) View more | - | 19 Sep 2024 | ||
repjssgmyr(lkbgruyzmc) = objdtrradf wtzrnwxqcr (hwhhaljepn, 8.3 - 10.5) View more | |||||||
Not Applicable | - | Port Delivery System with ranibizumab Q36W | dunjwbclly(lgxddxmbva) = No events of device dislocation were reported in either arm through W100 lzbkvssqtc (xhwuezhpks ) View more | - | 19 Sep 2024 | ||
(Control arm) | |||||||
Not Applicable | - | inbdjvbpnm(zmqvpucexb) = oiyctfjjkf dxfoxizird (jppbqzapnd ) | - | 19 Sep 2024 | |||
inbdjvbpnm(zmqvpucexb) = nxlicgmkgs dxfoxizird (jppbqzapnd ) | |||||||
Not Applicable | - | bxgdtiaxqd(ffvpekcdmp) = ekeqiaktup ygzttjyvqa (cvghqaytum ) View more | - | 19 Sep 2024 | |||
Phase 2/3 | Wet age-related macular degeneration vascular endothelial growth factor | - | nejudihgam(rlezmbggga) = BCVA remained stable for 5 years, with an observed BCVA Snellen equivalent of 20/40 and mean (95% CI) change from baseline of −1.8 ETDRS letters (−8.1, 4.4; n=17) at month 60 yhdravcmtc (zzulsndaig ) View more | Positive | 19 Sep 2024 | ||
Monthly intravitreal ranibizumab injections | |||||||
Not Applicable | - | mhpsawwfqw(cqpkfbgfvx) = 73% of eyes lacking DRIL demonstrated nearly three times higher odds of CMT reduction compared to eyes with DRIL present (OR 2.9) cusnifwxut (khgctryrjl ) View more | - | 19 Sep 2024 | |||